Protagonist Therapeutics, Inc. (PTGX) États Financiers et Données Historiques

Protagonist Therapeutics, Inc. (PTGX) — Prix $142.84 HealthcareBiotechnology — NASDAQ

Derniers résultats publiés:

États financiers détaillés de Protagonist Therapeutics, Inc. (PTGX): compte de résultat, bilan et tableau de flux de trésorerie. Suivez l'évolution des marges, de la dette, de la liquidité et de la rentabilité d'une année sur l'autre avec jusqu'à 20 ans d'historique.

Résumé de l'Analyse

Protagonist Therapeutics, Inc. a enregistré un chiffre d'affaires de $46.0M sur le dernier exercice, avec un CAGR sur 5 ans de 10.0%.

Marges des 12 derniers mois: marge brute 97.3%, marge opérationnelle -343.6%, marge nette -282.8%.

Au prix actuel de $142.84, PTGX affiche des résultats négatifs (PER non significatif) et un ROE de -21.17%. La capitalisation boursière s'établit à $9.2B.

Compte de Résultat (10 ans)

Année2016201720182019202020212022202320242025
Revenus0$20.1M$30.9M$231000$28.6M$27.4M$26.6M$60.0M$434.4M$46.0M
Coût des Ventes$31700000000000$1.2M
Marge Brute-$317000$20.1M$30.9M$231000$28.6M$27.4M$26.6M$60.0M$434.4M$44.8M
R&D$25.7M$46.2M$59.5M$65.0M$76.0M$126.0M$126.2M$120.2M$138.1M$159.3M
Frais Généraux$7.0M$11.8M$13.7M$15.7M$18.6M$27.2M$31.7M$33.5M$43.5M$44.9M
Charges Opérationnelles$32.7M$58.0M$73.2M$80.8M$93.1M$153.2M$158.0M$153.7M$181.6M$202.9M
Résultat Opérationnel-$32.7M-$37.9M-$42.3M-$80.5M-$64.5M-$125.8M-$131.4M-$93.7M$252.8M-$158.1M
EBITDA-$32.3M-$36.6M-$39.2M-$77.0M-$63.6M-$122.8M-$124.0M-$75.6M$280.2M-$128.1M
Charges d'Intérêt000$169000$59800000000
Résultat Avant Impôts-$37.2M-$37.0M-$39.7M-$77.9M-$64.8M-$125.6M-$127.4M-$79.0M$279.4M-$129.3M
Impôts00-$799000-$691000$1.3M000$4.2M$838000
Résultat Net-$37.2M-$37.0M-$38.9M-$77.2M-$66.2M-$125.6M-$127.4M-$79.0M$275.2M-$130.1M
BPA$-5.72$-2.09$-1.74$-2.98$-1.92$-2.65$-2.52$-1.39$4.47$-2.05
BPA Dilué$-5.72$-2.09$-1.74$-2.98$-1.92$-2.65$-2.52$-1.39$4.23$-2.05
Actions en Circulation (Diluées)$6.5M$17.7M$22.4M$25.9M$34.4M$46.3M$49.0M$56.8M$65.1M$63.6M

Compte de Résultat (Trimestriel)

Année2025-Q32025-Q42026-Q12026-Q2
Revenus$4.7M$7.4M$56.4M$213.5M
Marge Brute$4.7M$7.4M$56.0M$213.5M
Résultat Opérationnel-$46.4M-$50.4M-$3.6M$158.8M
EBITDA-$39.0M-$43.3M$2.7M$165.1M
Résultat Net-$39.3M-$44.4M$3.8M$162.8M
BPA$-0.62$-0.69$0.06$2.47
BPA Dilué$-0.62$-0.69$0.05$2.29

Bilan (10 ans)

Année2016201720182019202020212022202320242025
Trésorerie$21.1M$106.0M$82.2M$33.0M$117.4M$123.7M$125.7M$186.7M$97.2M$128.4M
Placements à Court Terme$56.5M$38.0M$46.6M$100.0M$188.5M$203.2M$111.6M$154.9M$321.7M$439.0M
Créances$2.2M$1.8M$4.6M$6.8M$3.8M$5.3M$52000$10.3M$168.5M$4.5M
Stocks-$7.7M-$8.7M$2.1M0000000
Actifs Courants$83.2M$150.9M$137.5M$145.3M$315.6M$340.7M$243.1M$355.6M$591.6M$577.6M
Immobilisations Corporelles$562000$879000$861000$7.7M$6.4M$6.7M$4.6M$2.1M$12.6M$11.7M
Goodwill0000000000
Actifs Incorporels0000000000
Actifs Totaux$94.0M$163.7M$139.5M$154.9M$324.5M$347.7M$247.9M$358.0M$744.7M$669.9M
Dettes Fournisseurs$1.2M$1.3M$5.7M$2.8M$3.1M$1.6M$3.6M$772000$1.6M$5.3M
Dette à Court Terme00000000$510000$2.3M
Passifs Courants$6.4M$42.6M$26.2M$35.4M$40.2M$44.0M$31.2M$21.3M$47.4M$45.4M
Dette à Long Terme000$9.8M000000
Passifs Totaux$6.4M$43.1M$27.0M$75.0M$44.9M$47.7M$32.3M$21.3M$69.4M$55.2M
Réserves-$64.6M-$101.5M-$140.5M-$217.7M-$283.8M-$409.4M-$536.8M-$615.7M-$340.5M-$470.7M
Capitaux Propres-$64.6M-$101.5M-$140.5M$80.0M$279.6M$300.0M$215.6M$336.7M$675.3M$614.7M
Dette Totale000$17.0M$6.0M$5.9M$3.7M$1.1M$10.9M$10.3M
Dette Nette-$77.6M-$144.0M-$128.9M-$116.0M-$299.9M-$321.0M-$233.7M-$340.5M-$408.0M-$557.0M
Fonds de Roulement$76.8M$108.4M$111.3M$109.9M$275.4M$296.7M$211.9M$334.3M$544.2M$532.1M

Bilan (Trimestriel)

Année2025-Q32025-Q42026-Q12026-Q2
Trésorerie$113.7M$128.4M$193.7M$420.1M
Actifs Totaux$701.7M$669.9M$697.5M$885.5M
Passifs Totaux$56.3M$55.2M$42.0M$44.0M
Capitaux Propres$645.4M$614.7M$655.5M$841.5M
Dette Totale$10.7M$10.3M$9.8M$9.2M

Tableau de Flux (10 ans)

Année2016201720182019202020212022202320242025
Résultat Net-$37.2M-$37.0M-$38.9M-$77.2M-$66.2M-$125.6M-$127.4M-$79.0M$275.2M-$130.1M
Amortissements$317000$406000$527000$2.5M$2.6M$2.8M$3.4M$3.3M$2.9M$1.3M
Stock-based Compensation$2.1M$4.2M$6.9M$8.4M$7.9M$16.4M$24.2M$29.3M$37.6M$46.0M
Variation du BFR-$112000$35.6M-$18.0M$26.1M-$19.0M-$3.3M-$7.8M-$19.5M-$122.6M$146.2M
Cash Flow Opérationnel-$30.0M$3.9M-$49.9M-$41.5M-$72.5M-$107.9M-$108.1M-$70.2M$184.2M$57.7M
CapEx-$379000-$666000-$486000-$967000-$471000-$1.1M-$795000-$609000-$1.4M-$1.6M
Acquisitions$3200000$52.7M$90.5M$14.8M-$91.5M000
Rachat d'Actions0000000000
Dividendes Payés0000000000
Free Cash Flow-$30.4M$3.2M-$50.4M-$42.5M-$73.0M-$109.0M-$108.9M-$70.8M$182.8M$56.1M

Tableau de Flux (Trimestriel)

Année2025-Q32025-Q42026-Q12026-Q2
Cash Flow Opérationnel-$1.9M-$37.0M-$48.9M$219.1M
CapEx-$88000$1.4M-$215000-$168000
Free Cash Flow-$2.0M-$35.5M-$49.2M$218.9M
Dividendes Payés0000
Stock-based Compensation$10.6M$10.7M$14.5M$14.0M

Croissance et Marges (10 ans)

Année2016201720182019202020212022202320242025
Croissance Revenus (annuelle)+54.1%-99.3%+12293.1%-4.4%-2.8%+125.7%+624.1%-89.4%
Croissance Résultat Net (annuelle)+0.6%-5.3%-98.3%+14.3%-89.8%-1.5%+38.0%+448.5%-147.3%
Croissance BPA (annuelle)+63.5%+16.7%-71.3%+35.6%-38.0%+4.9%+44.8%+421.6%-145.9%
Variation Actions (annuelle)+172.1%+26.4%+15.8%+32.8%+34.7%+5.9%+15.7%+14.6%-2.3%
Croissance FCF (annuelle)+110.6%-1673.1%+15.7%-71.7%-49.4%+0.0%+35.0%+358.0%-69.3%
Marge Brute100.0%100.0%100.0%100.0%100.0%100.0%100.0%100.0%97.3%
Marge Opérationnelle-188.9%-136.7%-34857.6%-225.4%-460.0%-494.2%-156.1%58.2%-343.6%
Marge EBITDA-182.2%-126.7%-33335.9%-222.0%-448.8%-466.6%-126.1%64.5%-278.4%
Marge Nette-184.2%-125.9%-33414.3%-231.1%-458.9%-479.3%-131.6%63.3%-282.8%
Marge FCF16.0%-163.1%-18395.7%-254.8%-398.3%-409.8%-118.1%42.1%121.9%
Taux d'Imposition Effectif-0.0%-0.0%2.0%0.9%-2.0%-0.0%-0.0%-0.0%1.5%-0.6%

Données par Action (10 ans)

Année2016201720182019202020212022202320242025
FCF par Action$-4.67$0.18$-2.26$-1.64$-2.12$-2.35$-2.22$-1.25$2.81$0.88
Dividende par Action$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00
Actions en Circulation (Basiques)$6.5M$17.7M$22.4M$25.9M$34.4M$46.3M$49.0M$56.8M$61.6M$63.6M

Quoi regarder en Biotech

La plupart des petites biotechs perdent de l'argent. Les analyser avec le P/E n'a aucun sens — regardez cash et pipeline.

Rentabilité

Rentabilité des capitaux propres-21.17%
Rentabilité du capital investi-25.23%
Rentabilité des actifs-19.43%
Marge brute97.34%
Marge opérationnelle-343.63%
Marge nette-282.83%

Santé financière

Dette / Capitaux propres0.02
Ratio de liquidité12.71
Piotroski F-Score3
Altman Z-Score59.63

Ratios Clés (10 ans)

Année2016201720182019202020212022202320242025
PER-3.84-9.95-3.87-2.37-10.50-12.91-4.33-16.508.64-42.60
P/B-2.21-3.62-1.072.282.485.282.483.873.529.03
P/V0.0018.344.87790.2724.2257.9120.1321.695.47120.66
Marge Brute0.0%100.0%100.0%100.0%100.0%100.0%100.0%100.0%100.0%97.3%
Marge Opérationnelle0.0%-188.9%-136.7%-34857.6%-225.4%-460.0%-494.2%-156.1%58.2%-343.6%
Marge Nette0.0%-184.2%-125.9%-33414.3%-231.1%-458.9%-479.3%-131.6%63.3%-282.8%

Entreprises liées: ACLX · AKRO · ALKS · CRNX · IMVT · KYMR · NAMS

Explorer le secteur: Healthcare · Biotechnology

Plus de sections de PTGX: Vue d'ensemble · Valorisation · Statistiques · Estimations · Technique · Actionnariat · Actualités · Événements

Découvrir plus: Radar — signaux d'actions sous-évaluées · Académie d'Investissement — apprenez à analyser les actions